Evidence map›Paper›PMID 39836305›Full record

ReviewJournal of gastrointestinal cancer2025

A Review of Circulating Tumor DNA (ctDNA) in Pancreatic Cancer: Ready for the Clinic?

Purvi Jonnalagadda, Virginia Arnold, Benjamin A Weinberg

Abstract readReview
PubMed Publisher
In one paragraph

Review in Journal of gastrointestinal cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Article
  6. Review
  7. Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Purvi JonnalagaddaGeorgetown University, Washington, DC, USA.
Virginia ArnoldUniversity of South Carolina, Columbia, SC, USA.
Benjamin A WeinbergRuesch Center for the Cure of Gastrointestinal Cancers, Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC, USA. baw12@gunet.georgetown.edu.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Pancreatic ductal adenocarcinoma is a devastating disease which is associated with an increase in cancer-related death in the USA. The minority of patients are cured by surgery alone and typically require adjuvant chemotherapy in order to improve clinical outcomes. Circulating tumor DNA (ctDNA) is an emerging technology whereby microscopic levels of minimal residual disease (MRD) can be detected in the bloodstream. Circulating KRAS mutations are frequently studied given that they are present in over 90% of pancreatic cancers. Other assays utilize whole exome sequencing and/or methylomics to detect MRD. We demonstrate that ctDNA has prognostic and predictive capabilities in patients with both resectable and unresectable pancreatic ductal adenocarcinoma. ctDNA opens the door to novel therapeutic options and is already being integrated into ongoing clinical trials.

Indexed as

Biomarkers, TumorCarcinoma, Pancreatic DuctalCirculating Tumor DNAPancreatic NeoplasmsHumansMutationNeoplasm, ResidualPrognosisProto-Oncogene Proteins p21(ras)Biomarkers, TumorCirculating Tumor DNAKRAS protein, humanProto-Oncogene Proteins p21(ras)Circulating tumor DNA (ctDNA)First-line metastaticMinimal residual disease (MRD)Pancreatic ductal adenocarcinoma

Identifiers

PMID39836305

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.